Table 1.

Patient tumor and treatment characteristics and clinical outcomes

PatientTumor histologyTumor locationTherapy before recurrenceBortezomib doseBortezomib schedule*Posttreatment biopsyLocal control on treatment; by 3 mo
1Recurrent SCCFloor of mouth and anterior triangle neckS, C, R0.6 mg/m2Twice weekly × 7 wk without breakYes50% tumor reduction; PD below field at 4 wk
2Recurrent SCCBase of tongue and anterior triangle neckS, C, R0.6 mg/m2Twice weekly × 7 wk without breakYesPD below field at 2 wk on treatment
3Recurrent SCCLeft base of tongue and valleculaS, R0.6 mg/m2Twice weekly × 7 wk with 2 wk breakYesStable disease on treatment; PD in field at 3 mo
4Recurrent SCCAnterior neck and parapharyngeal spaceS, C, R0.6 mg/m2Twice weekly × 7 wk without breakYesStable disease on treatment PD out of field at 1 wk
5Recurrent SCCAnterior neck with tracheal extensionS, R0.6 mg/m2Twice weekly × 7 wk without breakNo90% tumor reduction PD in field at 5 mo
6Recurrent SCCBase of tongueS, R0.6 mg/m2Twice weekly × 7 wk with 2 wk breakNo30% tumor reduction PD 3 mo
  • NOTE: S, surgery; C, chemotherapy; R, radiation; PD, progressive disease.

  • * Bortezomib given concurrently with fractionated radiotherapy (to 50-70 Gy) given daily (Monday to Friday).

  • Timing of all posttreatment biopsies is 24 h after initial treatment before the start of radiotherapy.

  • Based upon RECIST criteria, stable disease is defined as <30% tumor reduction and partial response is defined as >30% tumor reduction.